Country: United States
Language: English
Source: NLM (National Library of Medicine)
RISPERIDONE (UNII: L6UH7ZF8HC) (RISPERIDONE - UNII:L6UH7ZF8HC)
Heritage Pharmaceuticals Inc.
RISPERIDONE
RISPERIDONE 1 mg in 1 mL
ORAL
PRESCRIPTION DRUG
Risperidone is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see Clinical Studies (14.1) ]. Monotherapy Risperidone is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see Clinical Studies (14.2) ]. Adjunctive Therapy Risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults [see Clinical Studies (14.3) ]. Risperidone is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing
Risperidone oral solution USP, 1 mg/mL is a colorless to clear solution supplied in bottles of 30 mL. Risperidone oral solution should be stored at controlled room temperature 15°- 25°C (59°-77°F). Protect from light and freezing. Keep out of reach of children.
Abbreviated New Drug Application
RISPERIDONE- RISPERIDONE SOLUTION HERITAGE PHARMACEUTICALS INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RISPERIDONE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RISPERIDONE. RISPERIDONE ORAL SOLUTION USP INITIAL U.S. APPROVAL: 1993 WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED RISK OF DEATH. RISPERIDONE IS NOT APPROVED FOR USE IN PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. ( 5.1) RECENT MAJOR CHANGES Warnings and Precautions ( 5.8) 02/2017 INDICATIONS AND USAGE Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia ( 1.1) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2) Treatment of irritability associated with autistic disorder ( 1.3) DOSAGE AND ADMINISTRATION Recommended daily dosage INITIAL DOSE TARGET DOSE EFFECTIVE DOSE RANGE Schizophrenia : adults ( 2.1) 2 mg 4 to 8 mg 4 to 16 mg Schizophrenia : adolescents ( 2.1) 0.5 mg 3 mg 1 to 6 mg Bipolar mania – adults ( 2.2) 2 to 3 mg 1 to 6 mg 1 to 6 mg Bipolar mania: in children/adolescents ( 2.2) 0.5 mg 1 to 2.5 mg 1 to 6 mg Irritability associated with autistic disorder ( 2.3) 0.25 mg (Weight<20 kg) 0.5 mg (<20 kg) 0.5 to 3 mg 0.5 mg (Weight≥20 kg) 1 mg (≥20 kg) Severe Renal or Hepatic Impairment in Adults: Use a lower starting dose of 0.5 mg twice daily. May increase to dosages above 1.5 mg twice daily at intervals of at least one week. ( 2.4) Oral Solution: Can be administered directly from calibrated pipette or mixed with beverage (water, coffee, orange juice, or low-fat milk). ( 2.6) DOSAGE FORMS AND STRENGTHS Oral Solution: 1 mg/mL ( 3) CONTRAINDICATIONS Known hypersensitivity to risperidone, paliperidone, or to any excipients in Read the complete document